The Inflation Reduction Act (IRA) significantly reshapes Medicare Part D prescription drug costs for 2025 by introducing a $2,000 annual out-of-pocket cap, expanding low-income subsidies, and enabling Medicare to negotiate drug prices, aiming to lower beneficiary expenses and enhance access to essential medications. The landscape of prescription drug costs is perennially complex, particularly for Medicare […]